BACKGROUND: Mucin 4 (MUC4) is aberrantly expressed in colorectal adenocarcinomas (CRCs) but its prognostic value is unknown. METHODS: Archival tissue specimens collected from 132 CRC patients who underwent surgical resection without presurgery or postsurgery therapy were evaluated for expression of MUC4 by using a mouse monoclonal antibody and horseradish peroxidase. MUC4 expression levels were correlated with clinicopathologic features and patient survival. Survival was estimated by both univariate Kaplan-Meier and multivariate Cox regression methods. RESULTS: In both normal colonic epithelium and CRCs, MUC4 staining was localized primarily in the cytoplasm. The optimal immunostaining cutoff value (>or=75% positive cells and an immunostaining score>or=2.0), which was derived by using the bootstrap method, was used to categorize CRCs into groups of high expression (33 of 132 patients; 25%) or low expression (99 of 132 patients; 75%). Patients who had early stage tumors (stages I and II) with high MUC4 expression had a shorter disease-specific survival (log-rank; P=.007) than patients who had with low expression. Patients who had advanced-stage CRCs (stages III and IV) did not demonstrate such a difference (log-rank; P=.108). Multivariate regression models that were generated separately for patients with early stage and advanced-stage CRC confirmed that increased expression of MUC4 was an independent indicator of a poor prognosis only for patients who had early stage CRCs (hazard ratio, 3.77; 95% confidence interval, 1.46-9.73). CONCLUSIONS: The current results indicated that increased MUC4 expression is a predictor of poor survival in CRC, specifically for patients who have early stage tumors. Copyright (c) 2010 American Cancer Society.
BACKGROUND:Mucin 4 (MUC4) is aberrantly expressed in colorectal adenocarcinomas (CRCs) but its prognostic value is unknown. METHODS: Archival tissue specimens collected from 132 CRC patients who underwent surgical resection without presurgery or postsurgery therapy were evaluated for expression of MUC4 by using a mouse monoclonal antibody and horseradish peroxidase. MUC4 expression levels were correlated with clinicopathologic features and patient survival. Survival was estimated by both univariate Kaplan-Meier and multivariate Cox regression methods. RESULTS: In both normal colonic epithelium and CRCs, MUC4 staining was localized primarily in the cytoplasm. The optimal immunostaining cutoff value (>or=75% positive cells and an immunostaining score>or=2.0), which was derived by using the bootstrap method, was used to categorize CRCs into groups of high expression (33 of 132 patients; 25%) or low expression (99 of 132 patients; 75%). Patients who had early stage tumors (stages I and II) with high MUC4 expression had a shorter disease-specific survival (log-rank; P=.007) than patients who had with low expression. Patients who had advanced-stage CRCs (stages III and IV) did not demonstrate such a difference (log-rank; P=.108). Multivariate regression models that were generated separately for patients with early stage and advanced-stage CRC confirmed that increased expression of MUC4 was an independent indicator of a poor prognosis only for patients who had early stage CRCs (hazard ratio, 3.77; 95% confidence interval, 1.46-9.73). CONCLUSIONS: The current results indicated that increased MUC4 expression is a predictor of poor survival in CRC, specifically for patients who have early stage tumors. Copyright (c) 2010 American Cancer Society.
Authors: U Manne; R B Myers; C Moron; R B Poczatek; S Dillard; H Weiss; D Brown; S Srivastava; W E Grizzle Journal: Int J Cancer Date: 1997-06-20 Impact factor: 7.396
Authors: Dominik Alexander; Nirag Jhala; Chakrapani Chatla; Jon Steinhauer; Ellen Funkhouser; Christopher S Coffey; William E Grizzle; Upender Manne Journal: Cancer Date: 2005-05-15 Impact factor: 6.860
Authors: M Saitou; M Goto; M Horinouchi; S Tamada; K Nagata; T Hamada; M Osako; S Takao; S K Batra; T Aikou; K Imai; S Yonezawa Journal: J Clin Pathol Date: 2005-08 Impact factor: 3.411
Authors: Upender Manne; Chandrakumar Shanmugam; Venkat R Katkoori; Harvey L Bumpers; William E Grizzle Journal: Cancer Biomark Date: 2010 Impact factor: 4.388
Authors: Shiv Ram Krishn; Sukhwinder Kaur; Lynette M Smith; Sonny L Johansson; Maneesh Jain; Asish Patel; Shailendra K Gautam; Michael A Hollingsworth; Ulla Mandel; Henrik Clausen; Wing-Cheong Lo; Wai-Tong Louis Fan; Upender Manne; Surinder K Batra Journal: Cancer Lett Date: 2016-02-16 Impact factor: 8.679